Capricor Therapeutics Inc (NASDAQ: CAPR) on Tuesday, soared 1.28% from the previous trading day, before settling in for the closing price of $18.82. Within the past 52 weeks, CAPR’s price has moved between $2.90 and $23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 339.72% annually for the last half of the decade. The company achieved an average annual earnings per share of -44.41%. With a float of $40.01 million, this company’s outstanding shares have now reached $45.47 million.
In an organization with 102 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 95.71%, operating margin of -154.68%, and the pretax margin is -54151.28%.
Capricor Therapeutics Inc (CAPR) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Capricor Therapeutics Inc is 12.01%, while institutional ownership is 18.51%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.03 earnings per share (EPS) for the period topping the consensus outlook (set at -0.09) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -44.41% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Capricor Therapeutics Inc (CAPR) is currently performing well based on its current performance indicators. A quick ratio of 4.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.34 million. That was better than the volume of 1.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.56%. Additionally, its Average True Range was 1.74.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 78.17%, which indicates a significant increase from 63.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.50% in the past 14 days, which was lower than the 130.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.19, while its 200-day Moving Average is $8.10. However, in the short run, Capricor Therapeutics Inc’s stock first resistance to watch stands at $19.99. Second resistance stands at $20.93. The third major resistance level sits at $21.64. If the price goes on to break the first support level at $18.34, it is likely to go to the next support level at $17.63. Assuming the price breaks the second support level, the third support level stands at $16.69.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
Market capitalization of the company is 866.65 million based on 45,470K outstanding shares. Right now, sales total 25,180 K and income totals -22,290 K. The company made 2,260 K in profit during its latest quarter, and -12,560 K in sales during its previous quarter.
